The U.S. Food and Drug Administration (FDA) has granted commercial clearance for the Cerêve Sleep System, a prescription device that reduces latency to Stage 1 and Stage 2 sleep for people with insomnia, according to a company press release. The system, which comprises a software-controlled bedside device that cools and pumps fluid to a forehead pad that is worn through the night, is slated to launch during the second half of 2017.
